Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli‐D study

作者：Juan Liu, Yü Liu, Weiya Xu, Minlu Zhang, Qiong Huang, Qin Du, Lareina Kang, Felipe Lauand, Agustina Alvarez, Yanbing Li · 发表于：Diabetes Obesity and Metabolism · 年份：2025 · DOI：10.1111/dom.16646 · 被引用次数：3 · 研究领域：Diabetes Treatment and Management、Diabetes Management and Research、Diabetes Management and Education

Type 2 diabetes (T2D) remains a major public health burden globally, with China accounting for the highest number of affected individuals.1 Despite the widespread use of oral antidiabetic drugs (OADs), many patients fail to achieve glycaemic targets, increasing the risk of complications.2 In such cases, advanced therapies including fixed-ratio combinations (FRCs) or premixed insulin are recommended by the Chinese Diabetes Society.3 iGlarLixi, a once-daily FRC of insulin glargine 100 U/mL and GLP-1 RA lixisenatide, combines complementary actions of lowering basal and prandial glucose levels. It has demonstrated superior efficacy and safety compared to various comparators.4, 5 IDegAsp is a premixed insulin formulation of 70% insulin degludec and 30% insulin aspart, recommended as a once-daily regimen for Chinese with T2D who have suboptimal glycaemic control on OADs.6 The Soli-D study on Chinese adults with T2D suboptimally controlled with OADs showed that iGlarLixi had demonstrated non-inferiority and superiority to IDegAsp in reducing glycated haemoglobin (HbA1c) levels while also providing body weight benefits and a lower risk of hypoglycaemia.7 Beyond HbA1c, glucose time-in-range (TIR) derived from continuous glucose monitoring (CGM) or structured self-measured blood glucose (SMBG) offers actionable insights into glycaemic control.8 Derived TIR (dTIR) from 7-point SMBG profiles correlates with HbA1c and diabetic complications and has emerged as a meaningful endpoint in clin...